Astrantus’s Royalty Pharma RPRX Stock Holding History

Astrantus’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,678	Closed	-$426K	–	282
2021 Q4	$426K	Buy	+10,678	New	+$415K	0.32%	129

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Astrantus's RPRX Position: Q1 2022 in Review

Astrantus sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 10,678 shares — an estimated $426K sold.

Astrantus first reported a position in RPRX in Q4 2021 and held it in 1 quarter. The position peaked at $426K in Q4 2021. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

Astrantus reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
Astrantus sold 10,678 Royalty Pharma shares in Q1 2022, an estimated $426K.
Astrantus first reported a position in Royalty Pharma in Q4 2021 and held it in 1 quarter.
Astrantus's Royalty Pharma position peaked at $426K in Q4 2021.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.